The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Breast Cancer Research Foundation expands research program with Pfizer portfolio

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

THE BREAST CANCER RESEARCH FOUNDATION expanded its research program with a new collaborative breast cancer funding model, the BCRF Investigator-Initiated Drug Research Program. The received a three-year, $15 million grant from Pfizer to support this effort, as well as access to Pfizer’s portfolio of products. “It will encourage more creative, academic-driven research and give more...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Genetic counseling can improve genetic screening and accelerate clinical trial success

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.
By Ashley Cannon
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account